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A RANDOMIZED TRIAL OF INTRAVENOUS LABETALOL VERSUS ORAL 
NIFEDIPINE IN ACUTE BLOOD PRESSURE CONTROL IN HYPERTENSIVE 
EMERGENCIES OF PREGNANCY 
ABSTRACT 
OBJECTIVE: To compare safety and efficacy of intravenous labetalol with oral nifedipine to control 
blood pressure in hypertensive emergencies of pregnancy. 
DESIGN: A prospective randomized double blind comparative clinical trial 
SETTING: Patients admitted to Mahatma Gandhi Memorial government hospital, Tiruchirapalli. 
POPULATION: All pregnant women with sustained severe hypertension. 
METHODS: 106 consecutive patients were randomized to receive either intravenous labetalol in 
escalating doses of 20 mg, 40 mg, 80 mg, 80 mg, and 80 mg along with placebo tablets or nifedipine 10 
mg tablet orally along with placebo saline injections every 15 minutes up to five doses. The treatment is 
crossed over to the other group if reduction in both systolic and diastolic blood pressure ≤ 150/100 mm 
Hg does not occur. 
PRIMARY OUTCOME: The time taken to achieve a target blood pressure of both ≤ 150 mm Hg 
systolic and ≤ 100 mm Hg diastolic blood pressure. 
RESULTS: The median time take taken to attain target blood pressure was 45 minutes and 30 minutes in 
labetalol and nifedipine groups, respectively (P = 0.17). Median number of doses required was three and 
two to achieve blood pressure control in labetalol and nifedipine groups, respectively (P = 0.23). Cross 
over treatment was required in 9.40% in labetalol group and 11.30% in nifedipine group (P = 0.75). Side 
effects profile between the two drugs were also similar (P = 0.06) 
CONCLUSIONS: Intravenous labetalol and oral nifedipine are equally efficacious in controlling 
hypertensive emergencies of pregnancy. 
KEYWORDS: Preeclampsia, eclampsia, labetalol, nifedipine, sustained severe hypertension 
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INTRODUCTION 
Hypertension in pregnancy 
Hypertension in pregnancy, called a disease of degree is more of a sign than a disease 
by itself. With various advancements in the pathophysiology and various insights into 
the prevention of this disease, effective and timely control of hypertension is still the 
most imperative step in the management. 
Concerns akin to maternal morbidity, mortality and fetal and neonatal outcomes imply 
the impact of the disease in the obstetric population.   
The recent management option explores the various modalities in prediction and 
prevention of hypertension in pregnancy. However, the only effective therapy is the 
delivery of the fetus and placenta. The ancillary therapy is principally symptomatic 
and not directed at the fundamental cause.  
Effective pharmacologic therapy modifies the course of the disease. The effective use 
of anti-hypertensive therapy should be based on well designed controlled clinical 
trials and the experience of the clinician with the drugs. 
Hypertensive disorders complicate 5-10% of all pregnancies worldwide
 [1]
. In India, 
pregnancy induced hypertension, along with sepsis and hemorrhages, contributes to 
80% of the maternal mortality. Dangerous hypertension is a harbinger of 
  
cerebrovascular accidents, eclampsia, hypertensive encephalopathy and other end 
organ damage with a poor perinatal outcome
 [2]
. 
In order to mitigate the morbidity and the mortality, numerous antihypertensive agents 
are being used to control blood pressure in severe preeclampsia. Numerous reports 
signify that reducing severe hypertension reduces maternal death
 [3]
. 
Antihypertensive drug in pregnancy should effectively reduce the blood pressure of 
the mother, should not cause acute hypotension, should not have any deleterious 
effects on the fetus in utero, and should not have any adverse interaction with other 
drugs including those commonly used in pregnancy and in labour. The use of the drug 
should modify the course of the disease and it should prevent the development of 
complications. 
Hydralazine, diuretics and alpha methyl dopa are not recommended for use in severe 
hypertension as first line drugs due to adverse maternal, fetal outcomes and late onset 
of action of the latter. 
Labetalol was studied for its use in treatment of hypertensive urgencies in the general 
population. The smooth onset of action with minimal change in cardiac output and 
heart rate makes it a unique drug in the management of hypertensive emergency in 
pregnancy.  
Nifedipine has been evaluated for its immediate onset of action and ease of 
administration and no reported adverse effects on the mother or the fetus and on the 
course of labour.  
This study ventures to compare the pharmacodynamics of intravenous labetalol and 
oral nifedipine in patients with severe hypertension and to compare the maternal and 
fetal outcomes and adverse effects of both the drugs. 
 
  
  
  
AIM AND OBJECTIVE OF THE STUDY 
A recent CEMACH report recommends urgent and effective anti hypertensive 
treatment for patients with severe hypertension in pregnancy
 [3]
. 
Both intravenous labetalol and oral nifedipine
 [4]
 are used in acute blood pressure 
control in severe hypertension. 
The aim of the study is to compare intravenous labetalol with oral nifedipine in the 
management of acute blood pressure control in hypertensive emergencies of 
pregnancy. 
The present study is undertaken  
 To study the efficacy and safety of intravenous labetalol and oral nifedipine 
 To compare pharmacodynamics of intravenous labetalol and oral nifedipine 
including maternal and fetal side effect profile 
 To evaluate the maternal and fetal outcome in both the groups 
  
  
REVIEW OF LITERATURE 
Definition 
Hypertension in pregnancy goes by the definition of a sustained systolic blood 
pressure of 140 mm Hg or more and/or a diastolic blood pressure of 90 mm Hg or 
more detected for the first time during pregnancy after 20 weeks of gestational age. 
[5] 
The working group classification of hypertension in pregnancy is as follows. 
1. Gestational hypertension 
2. Preeclampsia 
3. Eclampsia 
4. Preeclampsia superimposed on chronic hypertension 
5. Chronic hypertension. 
The minimal criteria for the diagnosis of preeclampsia are blood pressure of ≥140/ 90 
mm Hg occurring after a gestational age of 20 weeks and presence of proteinuria 
≥300 mg/day or ≥ 1+ in urine dipstick proteinuria examination. 
The presence of the following features suggests the increased certainty of 
preeclampsia. 
 Blood pressure of ≥ 160/110 mm Hg 
 Proteinuria of ≥ 2g/day or a dipstick proteinuria estimation of ≥ 2+ 
 Newly detected rise in serum creatinine level of  > 1.2 mg/dl 
 Thrombocytopenia, with platelet count < 1,00,000/ µL 
 Increased serum lactate dehydrogenase levels indicating microangiopathic 
hemolysis 
 Elevated liver enzymes 
 Persistent headache and visual disturbances 
 Persistent epigastric pain 
  
Severe preeclampsia is defined as severe hypertension with proteinuria or 
hypertension with severe proteinuria constituting 5 g/day or more. The definition 
includes multisystem involvement and also comprises imminent signs and symptoms. 
[6] 
Epidemiology 
Though mild disease occurs in about 2 to 7% of healthy nulliparous women, the 
incidence and severity of the disease are higher in high risk women. The risk factors 
may be couple, maternal or pregnancy related 
[7]
.  
Risk factors 
Couple related Maternal risk factors Pregnancy related risk 
factors 
Primiparity 
Limited sperm exposure 
Paternal factors 
Extremes of age 
Prior history of pregnancy 
induced hypertension 
Renal diseases 
Infections 
Susceptibility genes 
Family history 
Maternal infections 
Multifetal gestation 
Hydropic degeneration of 
placenta 
Hydrops fetalis 
 
 
Impact of pregnancy induced hypertension 
80% of maternal mortality is associated with pregnancy hypertension when combined 
with anemia and post partum hemorrhage. Hypertension in pregnancy predisposes to 
maternal and fetal complication. Coexistent anemia worsens the picture of 
hypertension in pregnancy.  
  
There is an increased incidence of placental abruption, preterm labour, preeclampsia, 
eclampsia, pulmonary edema, acute renal failure, intra cerebral hemorrhage and 
multi-organ failure.  
The fetal outcome is also poor in terms of preterm births, intrauterine growth 
restriction, placental insufficiency, side effects of the drugs used to control blood 
pressure, increased incidence of operative deliveries and intra uterine demise. Such is 
the impact of the disease so that early detection, prompt referral, proper medical and 
obstetric management will give a good maternal and fetal outcome. 
Pathogenesis 
Named a disease of theories, the etiology of pregnancy hypertension is still an 
unknown arena compounding susceptibility factors, genetic predispositions, 
environmental factors and immunological dynamics.  
The central elements predisposing to hypertensive state are- 
 Exaggerated inflammatory response 
 Inappropriate endothelial cell activation cascade 
 Abnormally shallow endovascular cytotrophoblastic invasion in the spiral 
arteries 
Endothelial cell activation 
Endothelial cell activation has been found to be a key factor in the development of 
preeclampsia in recent studies. Gant and co-workers have postulated that activated 
endothelium expresses less nitric oxide and crafts the milieu in favour of procoagulant 
substances. The activated endothelium expresses various factors which brings about 
increased sensitivity to infused pressor agents 
[8]
. 
  
  
Inflammation 
Pregnancy is a state of systemic inflammation because of the shedding of 
syncytiotrophoblast cells in to the maternal circulation. If this shedding becomes 
excessive, maternal innate immune system is activated and preeclampsia ensues. 
Redman’s two stage model of development of preeclampsia shows the role of 
placental ischemia-reperfusion injury. Recent studies point out that preeclampsia 
occurs due to certain auto immune disorders and infections including maternal 
periodontal diseases, urinary tract infections, Chlamydia and certain viral infections. 
Immunology 
Invasion of the trophoblast into the myometrium and decidua is controlled by the 
immune mechanism. The decidua contains lymphoid tissue, predominantly natural 
killer cells. The NK cells express KIR receptors, which recognize the HLA class I 
molecules. The NK cells secrete VEGF, PLGF, and Angiotensin 2 which bring about 
maternal placental bed vascular changes. Moffet King and colleagues studied the 
HLA C- NK cell receptor interaction. They state that each pregnancy is unique 
because of the NK cell- KIR- HLA C interaction. Mothers with absent or decreased 
KIRs which interact with HLA C group have increased propensity towards 
preeclampsia 
[9]
. 
Balance between pro and antiangiogenic factors 
Angiogenic factors like VEGF- A, PLGF are secreted by the villous, extra villous 
cytotrophoblasts, syncytiotrophoblast cells and decidual leukocytes. These factors 
induce the expression of nitric oxide and PGI2 which bring about vasodilatation. sFlt-1 
is a soluble version of VEGF receptor, which inhibits angiogenesis by reducing the 
circulating levels of VEGF and PDGF. Endoglin and sFlt-1 act in conjunction to bring 
  
about endothelial dysfunction. Their levels are seen to be raised weeks before clinical 
manifestations of preeclampsia 
[10]
. 
Pathophysiology  
1. Cardiovascular system 
In normal pregnancy, the plasma volume expands in the first and second trimesters up 
to 25%. Such an increase in plasma volume maintains fetal well-being. In women 
with severe preeclampsia, the rise in plasma volume is about 30 to 40% lesser than 
that of a normal pregnancy 
[11]
. Such patients have increased propensity towards the 
occurrence of IUGR, oligohydramnios and preterm labour. 
A sudden maternal weight gain of 1 kg/week or more over a period of two to three 
weeks or an increase in weight of more than 2 kg in one month is a dangerous 
harbinger of preeclampsia. The accelerated weight gain is due to the extracellular 
interstitial fluid collection as a result of a leaky microcirculation. 
Normal pregnancy is constituted by rise in heart rate; decrease in systemic vascular 
resistance and thereby an increase in cardiac output in a sequential order. In severe 
preeclampsia, the state of high cardiac output- low systemic vascular resistance 
balance is tilted towards low cardiac output- high systemic vascular resistance state. 
2. Renal system 
Preeclampsia induces glomerular endotheliosis which is said to be the hallmark renal 
lesion in preeclampsia. Oliguria in preeclampsia is most often a consequence of 
glomerular endotheliosis, intrarenal vasoconstriction and hypovolemia. These 
functional derangements may progress to acute tubular necrosis. Preeclampsia is a 
major cause of obstetric acute renal failure. Acute renal failure in preeclampsia is 
most often due to acute tubular necrosis or rarely due to bilateral cortical necrosis in 
cases with severe preeclampsia. Prompt delivery is expedited in most instances. 
  
3. Abnormal hemostasis 
Endothelial damage incites platelet activation and adherence at the predisposed sites 
namely uteroplacental bed, renal and hepatic vasculature. Various studies show that 
thrombocytopenia is the most common hemostatic abnormality in preeclampsia. In 
severe preeclampsia, the platelet count seldom falls below 50000/cu.mm 
[12]
. 
4. Liver 
In severe preeclampsia, sinusoidal blood flow is obstructed by fibrin like material. 
This in turn brings about capsular distension, which manifests most commonly as 
malaise
 [13]
. Non-specific viral syndrome like symptoms, epigastric distress, nausea 
and vomiting are other manifestations. HELLP syndrome, a variant of severe 
eclampsia, is heralded by hemolysis, elevated liver enzymes and low platelet count. It 
is caused by fibrin deposition in the arterioles which activate the coagulation system 
leading to lysis of erythrocytes and consumption of platelets. Liver suffers ischemia 
and hence periportal necrosis and subcapsular haemorrhages.  
Though delivery is the definitive management, use of magnesium sulphate 
prophylaxis, corticosteroids, use of blood and blood products help in ameliorating the 
symptoms. 
5. Brain 
Recent data from Port JD and colleagues suggest that hypertensive encephalopathy 
and over perfusion of brain occurring in severe preeclampsia are the inciting events in 
eclampsia 
[14]
. MRI studies of middle cerebral and posterior cerebral arteries show 
increased blood flow and Doppler studies show increased middle cerebral arterial 
velocity and increased cerebral perfusion pressure 
[15]
.  The prevention of acute severe 
rise in blood pressure thereby brings about a reduction in the morbidity and mortality 
of hypertensive patients. The use of anti- hypertensive medication thus prevents the 
  
occurrence of hypertensive encephalopathy, over perfusion of the brain and other 
cerebral complications. Recent CEMACH review has also recommended the control 
of acute rise in blood pressure in pregnancy. 
[3]
  
Eclampsia is defined as the occurrence of convulsions and/or coma in women with 
either gestational hypertension or preeclampsia. The seizures are Grandmal in 
character and are predominantly tonic-clonic. Head ache (82.5%), visual disturbances 
(44.4%) and upper abdominal pain (19%) are the forerunners of eclampsia. 
Hyperreflexia and clonus are said to be the hallmarks of severe preeclampsia. 
[16] 
Maternal complications 
Since hypertension in pregnancy is a multi organ disease, the complications involve 
almost all the organ systems. The patient may go in for eclampsia because of loss of 
cerebral auto regulation. The reported incidence is averaging 1 in 2000 deliveries. 
There is increased risk of operative deliveries and induction of labour done for the 
termination of the pregnancy. Abruption placenta occurs in about 1 to 4% of the 
patients.  
Complete or partial HELLP syndrome may supervene, which has an incidence 
ranging from 10 to 20%.  Coagulation dysfunction and full blown disseminated 
intravascular coagulation may occur. The raised systemic vascular resistance impairs 
the cardiac function leading to cardiac failure and pulmonary edema in about 2 to 5% 
of the patients. The risk of peripartum cardiomyopathy is increased. There is 
increased risk of adult respiratory distress syndrome probably due to management in 
high dependency unit with prolonged ventilator support. 
Fetal and perinatal outcome 
The outcome of the fetus or the neonate depends on the time of onset of hypertension 
and associated medical disorders. The incited prematurity can be iatrogenic or 
  
spontaneous. The outcomes are favourable in pregnancies with the onset of 
hypertension after 36 weeks of gestation. On the other hand, prognosis is not good in 
pregnancies with early onset hypertension, with the occurrence of placental 
insufficiency, IUGR, oligohydramnios, operative deliveries, abruptio placenta, effects 
of drugs used to control hypertension and convulsions, to name a few.  
The use of steroid to induce lung maturity in the case of preterm babies shows an 
improved outcome in terms of neonatal death, respiratory distress syndrome and intra 
ventricular hemorrhages. Fetal monitoring by cardiotocograph, non stress test 
biweekly and assessment of Doppler parameters weekly should be done. 
Prognosis and long term sequelae 
Severe preeclampsia is associated with a risk of 0.2% maternal mortality and 5% 
morbidity. The picture worsens with the occurrence of convulsions, endothelial 
dysfunction, vasospasm, small vessel thrombosis, intracranial haemorrhages, 
infarctions, acute tubular necrosis, multi-organ failure and coagulation abnormalities.  
The persistence of hypertension longer than a period of 12 weeks is said to chronic 
hypertension. The Follow Up collaborative group of Magpie trial has shown that 20% 
of the hypertensive mothers were followed up to be chronic hypertensives. Such 
patients are at an increased risk of cardiovascular morbidity. The time of onset of 
preeclampsia has been found to have an impact on the recurrence of preeclampsia in 
the future pregnancies. In patients with early onset preeclampsia, the risk of 
recurrence of preeclampsia in the subsequent pregnancy is found to be around 40%, 
while those with a late onset disease had a risk of recurrence of 25%. 
These patients have an increased propensity towards the development of ischemic 
heart diseases, neurovascular morbidity namely stroke, chronic renal disease and 
chronic hypertension. 
  
 Management options 
The natural course of preeclampsia is blocked at the secondary and tertiary levels of 
prevention. While early detection and prevention of occurrence of the disease per se is 
called for, the allaying of the severity of the disease and thereby reducing the 
complications prompt the mainstay in the present times. 
The morbidity and mortality of the preeclamptic mother and the neonate is 
considerably reduced with effective management.  
Evidence based practice and setting up of a protocol in the management of acute 
onset, severe hypertension in preeclampsia and eclampsia bring about an immense 
encouraging outcome. 
NICE guidelines state that intravenous or oral labetalol, oral nifedipine and 
intravenous hydralazine can be used as first line drugs in the management of severe 
preeclampsia. Consideration should be given for start of magnesium sulphate regime 
[17]
. 
Consensus exists regarding the management of severe preeclampsia, which develops 
after 34 weeks of gestation. The patient is delivered by induction or caesarean section 
depending on the obstetric and fetal indications. 
[18] 
Likewise, patients with a gestation of ≤ 34 weeks with imminent symptoms, signs of 
multi-organ dysfunction, non-reassuring fetal status, and eclampsia are delivered 
similarly 
[19]
. 
Controversy exists over the management of severe preeclamptic patients of less than 
34 weeks gestation with stable maternal and fetal indices. A recent review states that 
expectant management in a patient with severe preeclampsia at a gestational age 
between 24 and 33 weeks is a safe and a better practice and is said to bring about a 
  
prolongation of pregnancy for 7 to 10 days. Such a management brings about a 
favourable neonatal outcome.
 [19] 
The recommended criteria for termination of pregnancy for the patients on expectant 
management are as follows. 
 Uncontrolled blood pressure 
 Imminent signs and symotoms of eclampsia 
 Non reassuring fetal cardiac status 
 Oligohydramnios  
 Oliguria 
 Elevated renal parameters especially serum creatinine concentration 
 Elevated liver enzymes  
 Development of HELLP syndrome 
 Pulmonary edema 
In the case of pregnancies with severe preeclampsia with a gestational age of less than 
24 weeks, the expectant management is said to give a high maternal morbidity with 
limited perinatal benefit. 
[20] 
1.  General management 
The mainstay in the management relies on reduction of blood pressure, prevention of 
convulsions, with careful monitoring of input and output and fetal monitoring. 
Patients with severe preeclampsia are hospitalized. The patients should be monitored 
for blood pressure every fifteen minutes till reduction to a systolic blood pressure of 
150 mm Hg and a diastolic blood pressure of less than 100 mm Hg.  
Laboratory investigations including complete blood count including platelet count, 
liver enzyme study, coagulation profile and spot urine protein creatinine ratio for 
screening are undertaken. Fetal assessment with fetal heart rate monitoring, umbilical 
artery Doppler studies, ultra sonogram every two weeks are good practice principles. 
  
A steroid for fetal lung maturity is indicated in pregnancies with less than 34 weeks 
gestation if delivery is awaited. 
2. Antihypertensive management 
A wide armamentarium of drugs is available with various modes of administration, 
utilized for various indications. The most commonly used drugs are labetalol, 
nifedipine, alpha methyl dopa and hydralazine, to name a few. Gradual and prompt 
reduction of blood pressure in severe preeclampsia is warranted by the administration 
of intermittent dosage of drugs or by a continuous monitored infusion. Combinational 
use of drugs is not encouraged since their compound effect may bring about a 
hypotensive episode.  
Consensus exists regarding the maintenance of blood pressure at 140 to 160 mm Hg 
systolic and 90 to 105 mm Hg diastolic range during the treatment of hypertension in 
pregnancy. A sudden steep decline of blood pressure is said to compromise the 
uteroplacental blood flow and thereby the fetus. The patient should be monitored for 
the anti hypertensive effect of the drug and occurrence of adverse affects in mother or 
the fetus. The dosage is modified according to the response.  
Numerous studies are done comparing hydralazine with labetalol in acute blood 
pressure control. Since the former is associated with many poor outcomes namely 
increased caesarean sections, placental abruption and fetal heart rate abnormalities, 
the use of hydralazine is not recommended. 
Many studies show the efficacy and rapidity of action of oral and intravenous 
labetalol in mild to moderate hypertension and acute severe hypertension of 
pregnancy respectively. Use of intravenous labetalol and oral nifedipine has found its 
place in the tertiary care protocol in the management of severe preeclampsia and 
eclampsia in most of the states in India.  
  
Labetalol 
 NH2 
 OH 
 
 
NH 
         OH 
 
Labetalol, first of its kind, is a combined α- and β-adrenergic blocker. The chemical 
formulation contains four stereoisomers with distinct action profiles on the receptor 
subtypes. The available commercial preparation is a racemic mixture of two pairs of 
chiral isomers. 
 The ration of α to β blockade is 1: 7 following intravenous administration. The 
systolic and diastolic fall in blood pressure is attributed to both α1 and β1 blockade. 
Vasodilatation is brought about by β2 weak agonistic activity.  
The reduction in systemic vascular resistance with no change in heart rate and cardiac 
output is by α blockade. It reduces blood pressure smoothly and rapidly. There is a 
decrease in cardiac index following both oral and intravenous administration.   
Labetalol is a pregnancy category C drug. It crosses the placenta and small amounts 
are secreted via breast milk. Sibai in his study prefers the use of labetalol 
[21]
. The 
protocol issued by NHBPEP Working Group (2000) and American College of 
Obstetricians and Gynaecologists (2002) recommends the usage of 20 mg initial 
intravenous dose in the management of acute severe hypertension in pregnancy. The 
dose is doubled every ten minutes if there is no desired reduction in blood pressure till 
  
a total dose infusion of 220 mg per episode. The use of 20 mg initial dose of labetalol 
is preferred since the target concentration is reached more readily. 
 
                                         
 
Various studies conducted by Mabie and colleagues
[22] 
and Vigil-De Gracia
[23]
 and 
associates highlight the rapid action, better maternal and neonatal outcomes and 
minimal side effect profile of intravenous labetalol in comparison with intravenous 
hydralazine in antepartum and postpartum phases respectively. Lower doses were 
found to be effective for hydralazine group though with higher reporting of maternal 
and fetal adverse effects namely operative interventions, abruption placenta and fetal 
distress respectively. The above mentioned trial showed that labetalol is a safe and 
effective alternative drug when compared to hydralazine. 
In addition to its usage by intermittent bolus doses, Walker and co-workers 
recommend intravenous infusion regimen of labetalol as a second line treatment in the 
control of acute severe hypertension in pregnancy 
[24]
. 
  
Labetalol Pharmacokinetics 
100% bioavailability following i.v. 
administration
onset of action following i.v. is 2.5minutes
peak action at 5 minutes
50% plasma protein 
bound
T1/2 is 4.9 hours
Target concentration 
is 0.1mg/dl
Metabolized in liver 
via conjugation to 
glucuronide 
metabolites
  
Adverse reactions, contraindications and drug interactions 
The most commonly reported adverse effect is dizziness reported in about 20% of the 
patients. Other common adverse effects are nausea, fatigue, and light headedness. 
Since postural hypotension is common, left lateral positioning of the patient is advised 
when administering the drug intravenously.  
The usage of this drug is contraindicated in patients with obstructive airway diseases 
including bronchial asthma, cardiac failure and heart blocks. Caution is advised in the 
usage of drug in impaired liver function, diabetes mellitus and cardiac failure
 [25]
. 
Labetalol is associated with a smooth and rapid reduction in blood pressure. The 
administration can be through continuous infusion or intermittent regime. Adequate 
control of hypertension can then be followed by the intake of the drug via the oral 
route. The use of intravenous route entails prompt onset of action, adequate 
monitoring and dose titration.  
The drug does not have any adverse impact on the maternal systems, neonatal 
outcome, mode of delivery and further complications from the disease per se. Drug 
combinations are generally avoided in pregnancy hypertension for fear of interactions 
and drastic reduction in blood pressures. When labetalol is used along with nifedipine, 
monitoring is essential to avert a sudden fall in blood pressure. 
[26] 
Anti hypertensive drugs tend to compromise the placental circulation. No change in 
the umbilical blood flow is noted following the usage of labetalol according to the 
study by Baggio and co-workers 
[27]
. Hydralazine increased uterine artery resisitance 
index and labetalol did not have a significant adverse fetal circulatory disturbances. 
A clinical trial by Michael et al reports the accelerated fetal lung maturity by the 
usage of labetalol though further confirmatory studies are warranted 
[28]
. The use of 
labetalol in hypertensive pregnant patients who were taken up for caesarean section 
  
showed a decreased hypertensive response and reflex laryngospasm on intubation 
during general anesthesia 
[29]
.  
Nifedipine 
 
        D3C       N             CD3 
       
      CH3OOC                                   COOCH3  
      H                
          NO2  
 
 
It was discovered as early as 1800 that calcium influx is an essential part in smooth 
muscle contraction. Henceforth, L type calcium channel blockers are used in various 
indications. Nifedipine, a prototype of dihydropyridine group of calcium channel 
blockers has been studied extensively for its utility in hypertensive disorders of 
pregnancy. 
 The use of the drug has been established both in mild to moderate hypertensive 
disorders of pregnancy and severe preeclampsia for acute blood pressure control. 
Calcium channel had four subtypes of receptor, nifedipine is said to block the α1 
subtype and thus reduces the transmembrane calcium current, thereby producing a 
long lasting smooth muscle relaxation. 
[30] 
  
 
 Nifedipine effectively dilates the arterioles in preference to veins thus producing an 
effective vasodilatation without producing postural hypotension. It reduces the total 
peripheral resistance and thereby reduces the after load. This effect may produce an 
inconsequential amount of reflex tachycardia. There is a small increase in cardiac 
index. It has a rapid onset of action by oral route. The drug is available in immediate 
release and extended release tablets and capsules. The oral route provides an ease of 
administration without compromising the efficacy. The site of absorption of oral 
nifedipine is at the duodenum and jejunum. The gastric emptying time of pregnant 
women is found to be the same as in the non pregnant. However, there is a delay in 
the gastric emptying time during labour most often due to the use of analgesics. The 
elimination half life of nifedipine is said to be shortened with pregnant women 
implying a frequent dosing for a better anti hypertensive effect. Thus it shows that the 
oral route of administration is adequate enough to give a prompt onset of action in the 
blood pressure control. Sublingual route is not recommended since it produces a rapid 
fall of the blood pressure. NICE guideline recommends the use of oral nifedipine in 
blood pressure control in eclampsia and severe preeclampsia. 
Pharmacokinetics of Nifedipine 
45-70% oral bioavailability
Onset of action in 20 
minutes
peak action in 0.5 to 1 
hour
T1/2 is 4 hours
duration 4 to 8 hours
Metabolized in the 
liver
Excretion via renal 
80% and feces 20%
No need for dose 
reduction in renal 
disorders 
  
In a study conducted by Sibai et al the use of nifedipine has been compared with bed 
rest in pregnancy induced hypertension. The use of nifedipine has been shown to 
effectively reduce both systolic and diastolic blood pressure. However, there was no 
improved outcome in terms of prolongation of pregnancy or the fetal outcome 
[31]
. 
The antihypertensive effect was compared with placebo in a trial by Ismail et al 
[32]
, 
which shows that the mean arterial pressure was effectively reduced in nifedipine 
group and the drug brought about an increased urine output because of the 
vasodilatory effect.  
The use of nifedipine has been found to be effective and predictable in the trial by 
Fenakel et al. There was no drastic hypotensive response with the oral route. The 
study implies that nifedipine is superior to hydralazine 
[33]
.  
Nifedipine is a pregnancy category C drug. The drug crosses the placenta. There is no 
reported change in the uteroplacental blood flow. About 5% of the drug is secreted in 
the breast milk producing little or no neonatal hypotension. 
Adverse reactions, contraindications and drug interactions 
The most commonly reported adverse effects are ankle edema (10-30%), flushing 
(25%), dizziness (25%) and headache (10- 20%) 
[34]
. The only contraindication to its 
administration is hypersensitivity to the drug. 
Certain case reports warn about the theoretical interaction between magnesium 
sulphate administrations along with nifedipine. Both the drugs exhibit 
phamacodynamic synergism when administered together producing hypotension and 
neuromuscular blockade warranting close monitoring 
[35, 36]
. 
 
However, the renowned 
Magpie trial involving 10141 women with preeclampsia had 3029 women with 
concomitant magnesium sulphate and nifedipine administration. There was no 
significant hypotension or neuromuscular blockade reported in the study 
[37]
. 
  
The comparison of efficacy, duration of action and side effect profile of both the first 
line drugs namely labetalol and nifedipine in the management of severe preeclampsia 
can bring about better outcomes in the mother and the fetus. 
Alpha methyldopa 
Methyldopa, with an established long term safety
 [38]
, is an effective drug as a 
monotherapy in mild to moderate hypertension reducing the progression to severe 
preeclampsia. However, it is not useful in severe hypertension. The mechanism of 
action is by reduction of overall sympathetic outflow. The onset of action is in 4 to 6 
hours. It is metabolized in the liver and excreted through the kidney. The most 
common side effect is postural hypotension; excessive sedation and depression are 
also seen.  
Hydralazine 
Hydralazine acts by direct peripheral vasodilatation. It was the drug of choice in 
hypertensive emergencies in the past. The onset of action is 10 to 20 minutes. It 
produces significant hypotension producing no reassuring fetal cardiac status and fetal 
distress 
[39]
. The proposed mechanism is by release of noradrenaline. 
   
Magee et al in a meta-analysis reported worse maternal and fetal outcomes with 
hydralazine when compared to both nifedipine and labetalol, thus no longer 
recommending its use. There was an increased association of maternal hypotension 
(RR 3.29, 95% CI 1.50- 7.23), caesarean section (RR 1.30, 95% CI 1.08- 1.59), 
placental abruption (RR 4.17, 95% CI 1.19- 14.28), maternal oliguria (RR 4.00, 95% 
CI 1.22- 12.50) and low Apgar scores (RR 2.70, 95% CI 1.27- 5.88) following the use 
of hydralazine 
[40]
. 
  
  
Diazoxide 
Diazoxide is a benzothiazine derivative that acts by direct vasodilatation producing a 
rapid and long lasting effect. Since its usage is associated with maternal cerebral 
ischemia, maternal death and fetal distress 
[41]
, it is recommended only in extremely 
high blood pressures. Recently the use of minibolus doses of diazoxide constituting 
15 mg has no associated profound maternal hypotension 
[42]
. 
Sodium nitroprusside 
This drug has been used as a last resort in reducing high blood pressures. It acts by 
release of nitric oxide, which has vasodilator effects. It has a rapid onset of action, 
associated with the risk of rebound hypertension. Cyanide toxicity is reported in the 
fetus following its administration. The current usage, is hence limited to post partum 
usage or immediately prior to the delivery. 
[5] 
Nicardipine 
A calcium channel blocker, nicardipine is evaluated as a second line antihypertensive 
agent in pregnancy. Cabonne and colleagues studied the usage of nicardipine in the 
management of hypertension 
[43]
. The drug needs careful monitoring for possible renal 
shut down. 
Diuretics and other drugs 
Since diuretics can compromise the placental blood flow, the usage is solely limited in 
the management of pulmonary edema. Zeeman and co-workers, in their study 
elucidated that use of diuretics reduces an already depleted intravascular volume 
[44]
. 
Various other drugs like nimodipine, verapamil, intravenous ketanserin, and 
experimental drugs like calcitonin gene related peptide and cardiotonic steroids have 
also been evaluated for their utility in pregnancy hypertension. 
  
  
The use of ACE inhibitors is contra indicated in pregnancy because of teratogenecity, 
growth retardation, and respiratory distress syndrome. 
3.  Seizure prophylaxis  
Magnesium sulphate, with its neuroprotective and anticonvulsant properties has been 
compared extensively with other anticonvulsants or a placebo for its use in seizure 
prophylaxis and control of seizures 
[36, 45]
. In the Magpie trial, magnesium sulphate 
reduced the risk of eclampsia by 58% compared to placebo. The American College of 
Obstetricians and Gynecologists recommend the use of prophylactic magnesium 
sulphate in severe preeclampsia 
[46]
.  
Debate continues as regards the use of magnesium sulphate only to patients with an 
eclamptic seizure. But, a wider opinion is in favour of prophylactic treatment taking 
into account the significant mortality and long term morbidity of the mother and the 
neonate associated with the disease. However, universal prophylaxis is of no benefit. 
Alexander and associates issued a protocol considering the criteria based on National 
High Blood Pressure Education Program Working Group and the American College 
of Obstetricians and Gynecologists 
[47]
. 
The selective use of magnesium sulphate prophylaxis is indicated in any woman with 
new onset proteinuric hypertension, and including at least one of the following 
criteria. 
 Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥ 110 mm Hg 
 Proteinuria by dipstick measurement ≥ 2 + 
 Serum creatinine > 1.2 mg/dl 
 Platelet count < 100000/ cu. mm. 
 Aspartate transaminase elevated twice the upper limit of the normal value 
 Persistent headache or scotoma 
 Persistent mid epigastric or right upper quadrant pain 
  
Magnesium sulphate crosses the placenta and brings about a better outcome in the 
neonate. It is said to provide a cerebro-protective effect in the neonate, thereby 
reducing the incidence of cerebral palsy. 
The recommended dosage by Pritchard regime is constituted by loading dose and 
maintenance doses of 20% and 50% magnesium sulphate respectively. The loading 
dose of 4 gram by the intravenous route by which the drug is given over a period of 
not less than 10 minutes, along with 10 gram of the 50% drug administered 
intramuscularly at both buttocks. 
The maintenance dose involves alternate 5 gram 50% drug intramuscular injections at 
an interval of four hours on alternate buttocks. The drug regime is continued for 24 
hours past the delivery of the baby or 24 hours past the last fit in the case of 
eclampsia, whichever is later.  
Patients who are given magnesium sulphate are monitored for symptoms of 
magnesium toxicity namely loss of deep tendon reflexes, oliguria and respiratory 
depression.  
4.  Fluid management        
Preeclampsia is a state of intra vascular fluid depletion. The knowledge of fluid 
management comes from invasive hemodynamic monitoring in preeclampsia and in 
compromised states such as pulmonary edema, cardiac failure and renal shut down. 
The state of volume depletion with decreased cardiac output coupled with low oncotic 
pressure and capillary damage predisposes to pulmonary edema. The condition is 
further deteriorated by the injudicious use of volume expanders. The American 
College of Obstetricians and Gynecologists recommend invasive hemodynamic 
monitoring in severe cardiac disease, renal disorders, renal shutdown, refractory 
hypertension and pulmonary edema 
[45]
. 
  
Central venous pressure monitoring and Swan Ganz catheter insertion provide 
information regarding right ventricular and left ventricular functions respectively. 
Central venous pressure monitoring is validated in the correction of hypovolemia 
prior to antihypertensive therapy. Crystalloids are recommended in comparison to 
colloid administration. Lactated Ringer solution is administered at the rate of 60 ml to 
125 ml per hour in volume depleted states. Swan Ganz catheter is useful in conditions 
like pulmonary edema, uncontrolled hypertension, severe oliguria and multi organ 
failure. Both the procedures are associated with risks namely cardiac arrhythmias, 
pulmonary infarction and pulmonary hemorrhage.  
5. Steroids for lung maturity 
Accelerated lung maturity does not occur in preeclampsia 
[48]
. The perinatal outcome 
is dependent on the gestational age at the time of delivery. Corticosteroid treatment 
significantly reduced the neonatal morbidity and mortality in term of reduced neonatal 
death, respiratory distress syndrome and cerebro vascular hemorrhage 
[49]
. The benefit 
is limited to usage before 34 weeks of gestation. 
6. Fetal surveillance 
The protocol of fetal surveillance should be based on individual obstetric units as 
there is no consensus on the same. Correct assessment of gestational age, clinical 
examination and radiographic evaluation are the mainstay in the evaluation. The 
various modalities used are biophysical profile, assessment of amniotic fluid volume, 
cardiotocography and Doppler studies. No single modality is said to be superior to the 
other. Moreover, acute events like placental abruption or cord accidents cannot be 
predicted by these modalities. By far, the only surveillance modality that has shown to 
reduce the need for intervention is the umbilical artery Doppler velocimetry.  
  
  
7.  Labour and delivery 
The only cure for severe preeclampsia is termination of pregnancy 
[50]
. After 
stabilization of the blood pressure and providing adequate time for the corticosteroid 
to act so as to accelerate the fetal lung maturity, the patient should be promptly 
delivered by induction or caesarean section depending on the obstetric indication. The 
decision towards caesarean section depends on fetal condition, obstetric indications, 
Bishop Score and presence of labour. Various reports indicate that immediate or 
elective caesarean section confers no benefit 
[51]
. Induction of labour and vaginal 
delivery is not associated with adverse neonatal outcome 
[52]
. Oxytocin is 
administered during the active management of the third stage of labour. Ergometrine 
is contraindicated since its use is associated with cerebral vasospasm and hypertensive 
crisis. Monitoring of blood pressure, fluid balance and assessment of blood loss 
during delivery and adequate replacement is mandatory in hypertensive patients. 
8. Anesthetic considerations 
General practice principles recommend early involvement of anesthetists in patients 
with severe preeclampsia. The issues in consideration are anesthetic risk assessment, 
control of blood pressure, fluid management, seizure prophylaxis and anesthetic or 
analgesic considerations. Patients with organ failure require high dependency setting. 
Epidural anesthesia serves as a good adjunct to vaginal delivery by improving the 
renal and uteroplacental blood supply. The drugs to be avoided are ergometrine, 
ketamine and NSAIDs. Regional anesthesia is used in preference to general 
anesthesia. Close monitoring of vital signs is advised to avoid neuromuscular 
blockade in patients receiving magnesium sulphate regime. Low dose aspirin 
treatment is not a contraindication to regional anesthesia. Platelet count of less than 
50000/ cu. mm. is a contraindication for regional anesthesia.  
  
9. Postpartum management 
Seizure prophylaxis should be continued for 24 hours post partum since ≤44% of 
eclampsia is said to occur in the postpartum period. Anti-hypertensive drugs should 
be continued in the post partum period. The dosage is titrated according to the blood 
pressure control. Fluid balance monitoring, evaluation of hepatic, renal function and 
neurological status is validated. Since preeclampsia is a risk factor for thrombosis, 
thromboprophylaxis is administered unless surgically contraindicated. In-hospital 
stay, obesity, nephritic range proteinuria and operative delivery predispose to 
thrombosis. 
10.  Follow up 
Patients requiring medication for the control of blood pressure should be frequently 
reviewed. Since these patients are at an increased risk for adverse cardio vascular 
events, they should be under surveillance. Preconception counselling should be 
advised in the next pregnancy. Early onset severe disease should be evaluated for the 
presence of antiphospholipid antibody syndrome and further screening for 
thrombophilia if indicated 
[53]
. Contraceptive advice should also be provided.  
  
  
MATERIALS AND METHODS 
Materials and methods 
The study was conducted in a tertiary care teaching institution, Mahatma Gandhi 
Memorial Government Hospital, Tiruchirapalli in the Department of Obstetrics and 
Gynecology during the period of November 2012 to November 2013. Ethical 
committee clearance was obtained. 
One hundred and six consecutive patients satisfied the inclusion criteria and were 
recruited in the present study. 
Inclusion Criteria 
 Age – 18 to 35 years,  
 All pregnant women of 20 weeks gestation or more; excluding parity and 
booking status 
 Singleton pregnancy 
 Sustained severe hypertension: Systolic blood pressure ≥ 160 mm Hg ; 
diastolic  blood pressure ≥110 mm Hg; or a mean arterial pressure of  > 
125mmHg, lasting for 15 minutes or more in the past 4 hours on at least 2 
occasions. 
 Severe pre-eclampsia according to the consensus by the national high blood 
pressure education program, NHBPEP 2000. 
  
  
Exclusion Criteria 
 Eclampsia; HELLP syndrome 
 Bronchial asthma 
 Cardiac failure 
 Cardiac rhythm abnormalities 
 Chronic hypertension 
 Co-existent diseases like diabetes mellitus, rheumatic heart disease, congenital 
heart disease, renal or hepatic disorders  
 Multiple pregnancy 
 Exposure to either drugs prior to the study 
Study design 
This study is a prospective randomized double blind comparative clinical trial with 
randomization done using computer generated numbers. 
History 
A thorough history was elicited from the patients regarding age, parity, socio 
economic status, booking history, history suggestive of imminent symptoms. Their 
past history regarding bronchial asthma, cardiac diseases, prior drug intake for 
hypertension and other medical disorders were also obtained. 
Clinical examination 
A meticulous general examination and obstetric examination were carried out. On 
general examination, patients’ level of consciousness, degree of anemia, edema, 
jaundice, pulse rate, respiratory rate and temperature were ascertained.  
Blood pressure measurement was done with the mercury sphygmomanometer with the 
patient lying at an angle of 45 degrees. The mercury manometer placed at the level of 
patients’ heart. The measurements were taken in the right arm. The fifth Korotkoff, 
  
K5 sound was taken for diastolic blood pressure cut off. When K5 was not heard, 
muffling of the sound, K4 was considered. 
 Systemic examination and obstetric examination were carried out. Fetal wellbeing 
was ascertained with the use of cardiotocograph before and after the usage of anti-
hypertensive agents and other drugs.  
Investigations 
 Urine analysis 
 Complete blood count including platelet count 
 Blood grouping and typing 
 Renal function tests 
 Liver function tests 
 Peripheral smear study 
 Serum lactate dehydrogenase level 
 Ultrasonogram 
 Cardiotocograph 
Anti-hypertensive management 
After explaining the condition of the patient and getting prior informed consent, the 
pregnant women were randomized with computer generated numbers into two groups 
to receive either oral nifedipine or intermittent intravenous labetalol injections. 
Group A  
Fifty three patients were selected consecutively according to random numbers to 
receive the package containing intravenous labetalol injection in escalating doses of 
20 mg, 40 mg, 80 mg, 80 mg, 80 mg and a placebo tablet for every fifteen minutes 
until the target blood pressure of ≤ 150 / ≤ 100 mm Hg was achieved.  
  
Group B 
Fifty three patients were randomized to receive the package containing nifedipine 10 
mg tablet orally and intravenous placebo saline injections of 4 ml, 8ml, 16 ml, 16 ml, 
16 ml up to five doses, every fifteen minutes till the target blood pressure of ≤ 150 / ≤ 
100 mm Hg was achieved. 
The drug regime was crossed over to the other group if the initial regime was found 
unsuccessful after five cycles and blood pressure monitoring done. Patient was made 
to rest in bed in left lateral position. Blood pressure was noted every 15 minutes. Once 
the blood pressure was <150 / 100 mm Hg, no further trial medication was given until 
two consecutive readings were > 160/ 110 mm Hg. 
After successful control of blood pressure, further antihypertensive therapy was 
started two hours after the last trial medication.  
Obstetric management 
A careful obstetric examination was carried out. Bishop’s score was calculated. 
Fetal status is ascertained by cardiotocograph. Delivery of the fetus and placenta 
was expedited according to individual condition of the patients. Induction of labour 
was done with intra-cervical PGE2 gel instillation. Acceleration of labour was done 
with intravenous oxytocin infusion. Caesarean section was done for obstetric, fetal 
indications and failed inductions.  
Maternal side effect profile was recorded. Neonatal monitoring included number of 
admissions in the neonatal intensive care unit, occurrences of hypotension and 
hypoglycaemia. 
During the course of trial, maternal heart rate and fetal heart rate was monitored 
every 15 minutes. The trial was abandoned when there was non-reassuring fetal 
status and if maternal complications like hypotension, chest pain occurred.  
  
Outcome measures 
The primary outcome of this trial was the time taken to achieve a target blood 
pressure of ≤ 150 mm Hg systolic and ≤ 100 mm Hg diastolic in both the groups. 
Both had to be achieved.  
The secondary outcome measures include total number of antihypertensive doses to 
achieve the target blood pressure, both systolic and diastolic, any cardio-
tocographical abnormality, and maternal heart rate profile in the first hour, 
maternal hypotension, side effect profile and perinatal outcomes. 
After completion of the trial protocol, patients were asked to complete a 
questionnaire with yes or no answers on the symptoms of nausea, palpitation, 
flushing, dizziness, headache, and shortness of breath experienced. 
Statistical analysis 
All the data were entered consecutively in a predefined data information sheet and 
analysis was done using SPSS 20 software. Differences in categorical and 
continuous data were assessed using the Chi square test and Student‘t’ test, 
respectively. The tests were two sided. The statistical test is considered significant 
if the calculated p value is less than 0.05. 
  
  
ANALYSIS OF RESULTS 
TABLE – 1 
AGE DISTRIBUTION 
S. 
NO. 
AGE 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
 
 NUMBER % NUMBER % 
1.  
≤ 20 
YEARS 
10 18.90% 13 24.5% 
23 
(21.70%) 
2.  
21 to 29 
YEARS 
34 64.10% 32 60.4% 
66 
(62.30%) 
3.  
≥ 30 
YEARS 
9 17% 8 15.1% 17 (16%) 
MEAN (S.D.) 24.89 ( 4.25) 24.81 (4.22)  
STATISTICAL INFERENCE 
T = 0.092 Degree of freedom = 104 
P = 0.927 
 
There is no significant difference in ages of the recruited patients in both the groups. 
The mean age in labetalol and nifedipine groups was 24.89 and 24.81 years 
respectively. The majority of the patients had an age belonging to the category of 21 
to 29 years. 18.90 % and 24.50% from group A and group B respectively had ages 20 
years and below. 
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TABLE – 2 
PARITY 
S. 
NO. 
PARITY 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  PRIMI 40 75.47% 27 50.94% 67 (63.20%) 
2.  G2 7 13.20% 13 24.53% 20 (18.90%) 
3.  G3 3 5.66% 9 16.98% 12 (11.30%) 
4.  G4 3 5.66% 4 7.55% 7 (6.60%) 
STATISTICAL 
INFERENCE 
χ 2=7.465 
Degree of freedom = 3 
P= 0.058 > 0.05 
 
Parity was comparable in group A and group B. There is no significant difference in 
the parity of both the groups. Majority of the patients constituting 75.47% of group A 
and 50.94% of group B were primigravida. 63.20% enrolled in the study were 
primigravida. There is a higher incidence of preeclampsia in the first pregnancy. 
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TABLE – 3 
BOOKING STATUS 
S.NO. 
BOOKING 
STATUS 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  Booked 30 56.60% 28 52.80% 58(54.70%) 
2.  Unbooked 23 43.40% 25 47.20% 48(45.30%) 
STATISTICAL 
INFERENCE 
χ2= 0.152 
Degree of freedom = 1 
0.696 > 0.05 
 
The antenatal booking status did not differ significantly in both the groups. 43.40% 
and 47.20% from group A and B respectively were unbooked. 
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TABLE – 4 
GESTATIONAL AGE 
S. 
NO. 
GESTATIONAL 
AGE 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  ≤ 24 WEEKS 1 1.89% 2 3.77% 3 (2.83%) 
2.  25 to 28 WEEKS 7 13.21% 6 11.32% 
13 
(12.26%) 
3.  29 to 33 WEEKS 19 35.85% 17 32.08% 
36 
(33.96%) 
4.  34 to 36 WEEKS 22 41.51% 21 39.62% 
43 
(40.57%) 
5.  ≥ 37 WEEKS 4 7.55% 7 13.21% 
11 
(10.38%) 
STATISTICAL 
INFERENCE 
χ2= 1.363 
Degree of freedom = 4 
P = 0.851 > 0.05 
 
3 of the recruited patients, 1 in group A and 2 in group B had early onset disease at 
gestational age less than 24 weeks. The majority of the patients had gestational age of 
34 to 36 weeks constituting 43% on the whole with 41.51% and 39.62% respectively 
in group A and B. The recruited patients did not significantly differ in gestational age. 
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TABLE – 5 
BODY MASS INDEX 
S.NO 
BODY 
MASS 
INDEX 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  
25 to 29.99 
kg/m
2 
20 37.70% 20 37.70% 
40 
(37.70%) 
2.  ≥ 30 kg/m2 33 62.30% 33 62.30% 
66 
(62.30%) 
MEAN (S.D.) 30.93 (2.33) 30.90  (2.18)  
STATISTICAL 
INFERENCE 
χ2=1.000 
Degree of freedom = 1 
1.000 > 0.05 
 
Most of the patients namely 66, constituting 63.30% had a body mass index 
exceeding 30 belonging to the category obesity. There is no significant difference in 
the body mass index between the two groups.  
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TABLE – 6 
SYSTOLIC BLOOD PRESSURE 
S. 
NO. 
SYSTOLIC 
BLOOD 
PRESSURE 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  
160 to 169 
mm Hg 
23 43.40% 19 35.80% 
42 
(39.6%) 
2.  
170 to 179 
mm Hg 
17 32.10% 28 52.80% 
45 
(42.5%) 
3.  ≥ 180 mm Hg 13 24.50% 6 11.20% 
19 
(17.9%) 
MEAN (S.D.) 171 (9) 170 (8) 
STATISTICAL 
INFERENCE 
 
T= 0.477 Degree of freedom = 104 
0.635 > 0.05 
Not Significant 
 
The baseline systolic blood pressure of the patients recruited in both the groups did 
not differ significantly. The mean systolic blood pressure in intravenous labetalol 
group was 171 mm Hg whereas it was 170 mm Hg in oral nifedipine group. 43.40% 
of patients in group A had a blood pressure range of 160 to 169 mm Hg. 52.80% of 
patients in nifedipine group had a blood pressure range of 170 to 179 mm Hg. 
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TABLE – 7 
DIASTOLIC BLOOD PRESSURE 
S. NO. 
DIASTOLIC 
BLOOD 
PRESSURE 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  < 110 mm Hg 13 24.50% 15 28.30% 28(26.40%) 
2.  ≥ 110 mm Hg 40 75.50% 38 71.70% 78(73.60%) 
MEAN (S.D.) 112(7) 111(8) 
STATISTICAL 
INFERENCE 
T= 0.160 Degree of freedom = 104 
0.873 > 0.05 
Not Significant 
 
The baseline diastolic blood pressure did not vary significantly in the groups. The 
mean of the baseline diastolic blood pressure were 112 mm Hg and 111 mm Hg in the 
groups A and B, respectively. 75.50% and 71.70% in groups A and B had diastolic 
blood pressure more than 110 mm Hg. 
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TABLE – 8 
HEART RATE 
S. 
NO. 
HEART RATE 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  ≤ 90 per minute 39 73.60% 44 83% 83(78.30%) 
2.  
91 to 100 per 
minute 
12 22.60% 8 15.10% 20(18.90%) 
3.  
≥ 101 per 
minute 
2 3.80% 1 1.90% 3(2.80%) 
STATISTICAL 
INFERENCE 
χ2 = 1.435 
Degree of freedom = 2 
0.488 > 0.05 
 
There was no significant difference in the baseline heart rate between the groups. 
Majority of the patients in group A (73.60%) and group B (83%) had heart rate less 
than 90 per minute during the commencement of the study. 
  
  
TABLE – 9 
DEGREE OF PROTEINURIA 
S. 
NO. 
PROTEINURIA 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  1+ 21 39.62% 23 43.40% 44(41.50%) 
2.  2+ 13 24.53% 13 24.53% 26(24.50%) 
3.  3+ 19 35.85% 17 32.08% 36(34%) 
STATISTICAL 
INFERENCE 
χ2 =  0.202 
Degree of freedom = 2 
0.904 > 0.05 
 
Degree of proteinuria by dipstick estimation did not differ significantly in the groups 
A and B.  
  
  
TABLE – 10 
TIME TAKEN TO ACHIEVE TARGET BLOOD PRESSURE 
S.NO. TIME TAKEN 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
NUMBER % NUMBER % 
1.  15 minutes 4 7.55% 1 1.89% 
2.  30 minutes 8 15.09% 18 33.96% 
3.  45 minutes 20 37.74% 12 22.64% 
4.  60 minutes 13 24.53% 9 16.98% 
5.  75 minutes 3 5.66% 7 13.21% 
6.  ≥ 90 minutes 5 9.43% 6 11.32% 
STATISTICAL 
INFERENCE 
χ2 = 9.112 Degree of freedom = 6 
0.167 > 0.05 
No significant difference 
 
In group A, 20 patients, constituting 37.7% of the recruited reached the target blood 
pressure of less than 150/ 100 mm Hg in 45 minutes. 18 patients, constituting 34% of 
group B achieved the target blood pressure range by 30 minutes. The median time 
taken in group A is 45 minutes and that of group B is 30 minutes. Overall, there is no 
  
statistically significant change regarding the time taken to achieve the target blood 
pressure.   
  
  
FIGURE – 8 
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TABLE – 11 
NUMBER OF DOSES REQUIRED TO ACHEIVE TARGET BLOOD 
PRESSURE 
S. 
NO. 
NUMBER 
OF 
DOSES 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  1 4 7.5% 1 1.9% 5 (4.72%) 
2.  2 7 13.2% 18 34% 25 (23.58%) 
3.  3 19 35.8% 14 26.4% 33 (31.13%) 
4.  4 11 20.8% 9 17% 20 (18.87%) 
5.  5 7 13.2% 5 9.4% 12 (11.32%) 
6.  6 2 3.8% 2 3.8% 4 (3.77%) 
7.  7 3 5.7% 4 7.5% 7 (6.60%) 
STATISTICAL 
INFERENCE 
χ2 = 8.074 Degree of freedom = 6 
0.233 > 0.05 
Not Significant 
Excluding 5 patients in group A and 6 patients in group B, who required cross over 
treatment and achieved control of blood pressure at 105 minutes each, the rest of the 
patients  (31.10%) reached target blood pressure of < 150/ 100 mm Hg after three 
  
doses of antihypertensive. 35.80% of  patients enrolled in group A reached the target 
blood pressure on administration of three consecutive doses of antihypertensive, while 
34% of that in group B achieved target blood pressure in two doses of the drug 
administered. But the difference is not statistically significant.  
FIGURE – 9 
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TABLE – 12 
SYSTOLIC BLOOD PRESSURE AFTER ANTI HYPERTENSIVE 
TREATMENT 
S.NO. 
SYSTOLIC BLOOD 
PRESSURE AT 
REGULAR TIME 
INTERVAL 
GROUP A 
AND B 
MEAN 
(S.D.) 
STATISTICAL 
INFERENCE 
1.  
SYSTOLIC BP AT 
15 MINUTES 
LABETALOL 
(n=53) 
166 (11) T= 0.881 Df = 104 
0.380 > 0.05 
Not Significant 
NIFEDIPINE 
(n=53) 
164 (8) 
2.  
SYSTOLIC BP AT 
30 MINUTES 
LABETALOL 
(n=48) 
162 (10) T= 2.710 Df = 98 
0.008 < 0.05 
Significant 
NIFEDIPINE 
(n=52) 
156 (11) 
3.  
SYSTOLIC BP AT 
45 MINUTES 
LABETALOL 
(n=41) 
155 (11) T= -0.021 Df = 73 
0.984 > 0.05 
Not Significant 
NIFEDIPINE 
(n=34) 
155 (11) 
4.  
SYSTOLIC BP AT 
60 MINUTES 
LABETALOL 
(n=21) 
153 (11) T= -0.995 Df = 38 
0.326 > 0.05 
Not Significant 
NIFEDIPINE 
(n=19) 
156 (10) 
5.  
SYSTOLIC BP AT 
75 MINUTES 
LABETALOL 
(n=8) 
156 (13) T= 0.014 Df = 17 
0.989 > 0.05 
Not Significant 
NIFEDIPINE 
(n=11) 
156 (8) 
 
The mean fall in systolic blood pressure in group A is the maximum at 45 minutes and 
that in group B is at 30 minutes. On comparison, the fall in systolic blood pressure 
  
was significant at 30 minutes with a mean fall in group B of 156 mm Hg and that of 
group A was 162 mm Hg. The p value at 30 minutes is 0.008, which is significant. 
  
  
FIGURE – 10 A 
SYSTOLIC BLOOD PRESSURE AFTER ANTI HYPERTENSIVE 
TREATMENT 
 
FIGURE – 10 B
 
  
177
172
166 164
169
155
152
144 142 143
166
162
155 153
156
130
140
150
160
170
180
190
200
15 MIN 30 MIN 45 MIN 60 MIN 75 MIN
SY
ST
O
LI
C
 B
P
 IN
 m
m
 H
g
TIME IN MINUTES
GROUP A (LABETALOL)
+ 1 SD
- 1 SD
MEAN
172
167 166 166
164
156
145 144
146
148
164
156 155
156
156
130
135
140
145
150
155
160
165
170
175
15 MIN 30 MIN 45 MIN 60 MIN 75 MIN
SY
ST
O
LI
C
 B
LO
O
D
 P
R
ES
SU
R
E 
IN
 m
m
 H
g
TIME IN MINUTES
GROUP B (NIFEDIPINE)
+ SD
- SD
MEAN
  
TABLE – 13 
DIASTOLIC BLOOD PRESSURE AFTER ANTI HYPERTENSIVE 
TREATMENT 
S.NO. 
DIASTOLIC BLOOD 
PRESSURE AT 
REGULAR 
INTERVALS 
GROUP A 
AND B 
MEAN 
(S.D.) 
STATISTICAL 
INFERENCE 
1.  
DIASTOLIC BP AT 15 
MINUTES 
LABETALOL 
(n=53) 
106 (9) T= -0.571 Df = 104 
0.569 > 0.05 
Not Significant 
NIFEDIPINE 
(n=53) 
107 (8) 
2.  
DIASTOLIC BP AT 30 
MINUTES 
LABETALOL 
(n=49) 
101 (10) T= 0.371 Df = 99 
0.711 > 0.05 
Not Significant 
NIFEDIPINE 
(n=52) 
100 (12) 
3.  
DIASTOLIC BP AT 45 
MINUTES 
LABETALOL 
(n=41) 
96 (10) T= -1.827 Df = 73 
0.072 > 0.05 
Not Significant 
NIFEDIPINE 
(n=34) 
100 (10) 
4.  
DIASTOLIC BP AT 60 
MINUTES 
LABETALOL 
(n=21) 
95 (7) T= -1.134 Df = 39 
0.264 > 0.05 
Not Significant 
NIFEDIPINE 
(n=20) 
98 (10) 
5.  
DIASTOLIC BP AT 75 
MINUTES 
LABETALOL 
(n=8) 
96 (8) T= -0.827 Df = 17 
0.420 > 0.05 
Not Significant 
NIFEDIPINE 
(n=11) 
99 (9) 
The fall in diastolic blood pressure was comparable in both the groups. The labetalol 
group has a greater mean fall of diastolic blood pressure at 45 minutes. The mean fall 
was greatest at 30 minutes for the nifedipine group. On comparison of both the 
  
groups, the rate of fall of diastolic blood pressure was not found to be statistically 
significant. 
  
  
FIGURE – 11 A 
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TABLE – 14 
TREATMENT CROSS OVER 
S. NO. 
CROSS 
OVER 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  No 48 90.60% 47 88.70% 95(89.60%) 
2.  Yes 5 9.40% 6 11.30% 11(10.40%) 
STATISTICAL 
INFERENCE 
χ2= 0.101 Degree of freedom = 1 
0.750 > 0.05 
Not Significant 
 
Five patients (9%) out of 53 in group A and six patients (11%) in group B required 
cross over treatment to the alternate group. All the eleven patients from both the 
groups achieved control of blood pressure within 105 minutes of the commencement 
of the study. 
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TABLE – 16 
HEART RATE 
S. 
NO. 
HEART RATE AT 
REGULAR 
INTERVALS 
GROUPS A 
AND B 
MEAN 
(S.D.) 
STATISTICAL 
INFERENCE 
1.  
HEART RATE AT 15 
MINUTES 
LABETALOL 
(n=53) 
86(10) T= 1.104 Df = 104 
0.272 > 0.05 
Not Significant 
NIFEDIPINE 
(n=53) 
84(9) 
2.  
HEART RATE AT 30 
MINUTES 
LABETALOL 
(n=49) 
85(9) T= -2.166 Df = 99 
.033 < 0.05 
Significant 
NIFEDIPINE 
(n=52) 
89(8) 
3.  
HEART RATE AT 45 
MINUTES 
LABETALOL 
(n=42) 
84(8) T= -5.653 Df = 75 
.000 < 0.05 
Significant 
NIFEDEIPINE 
(n=35) 
93(5) 
4.  
HEART RATE AT 60 
MINUTES 
LABETALOL 
(n=23) 
82(8) T= -5.471 Df = 40 
.000 < 0.05 
Significant 
NIFEDIPINE 
(n=19) 
94(5) 
5.  
HEART RATE AT 75 
MINUTES 
LABETALOL 
(n=13) 
81(8) T= -4.594 Df = 22 
.000 < 0.05 
Significant 
NIFEDIPINE 
(n=11) 
95(5) 
 
The difference in heart rate between labetalol and nifedipine groups was significant 
from 30 minutes of the commencement of the study. Patients in labetalol group had a 
progressive reduction in heart rate and that in nifedipine group showed a progressive 
rise in the same.  
  
  
  
FIGURE – 13 A 
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TABLE – 17 
INDUCTION 
S.NO. INDUCTION 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  No induction 6 11.30% 3 5.70% 9(8.50%) 
2.  
Induction with 
cerviprime gel 
47 88.70% 50 94.30% 97(91.50%) 
STATISTICAL 
INFERENCE 
χ2=1.093 Degree of freedom = 1 
0.296 > 0.05 
Not Significant 
 
Delivery of the baby was expedited after control of blood pressure. Induction with 
cerviprime gel was done to 88.70% and 94.93% of patients in group A and B after 
stabilizing the blood pressure.  
  
  
TABLE – 18 
INDUCTION DELIVERY INTERVAL 
S. NO. 
INDUCTION 
DELIVERY 
INTERVAL 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
NUMBER % NUMBER % 
1.  Less than 12 hrs 37 69.80% 34 64.20% 
2.  More than 12 hrs 16 30.20% 19 35.80% 
MEAN (S.D.) 13 (11) 13(11) 
STATISTICAL INFERENCE 
T = -0.274 Degree of freedom = 104 
0.785 > 0.05 
Not Significant 
 
91.20% of the recruited patients were induced. 64.20% of the patients delivered 
within 12 hours of admission. There was no statistically significant variation in the 
groups A and B. 
  
  
FIGURE – 14 
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TABLE – 19 
MODE OF DELIVERY 
S. 
NO. 
MODE OF 
DELIVERY 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
Total 
(n=106) 
NUMBER % NUMBER % 
1.  Labour naturale 35 66% 39 73.60% 74(69.80%) 
2.  LSCS 18 34% 14 26.40% 32(30.20%) 
STATISTICAL 
INFERENCE 
χ2 = 0.716 Degree of freedom = 1 
0.397 > 0.05 
Not Significant 
 
Caesarean section was done for obstetric indications. 74 patients, comprising 66% of 
group A and 73.6% of group B delivered vaginally. There were no cases of 
instrumental delivery in both the groups. Rest of the patients ended up in caesarean 
section. The outcome did not differ significantly in both the groups. 
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TABLE – 20 
BIRTH WEIGHT OF THE BABY 
S. 
NO. 
BIRTH 
WEIGHT OF 
THE 
NEWBORN 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  1.5 to 1.9 kg 7 13.20% 9 17% 16(15.10%) 
2.  2 to 2.4 kg 25 47.20% 24 45.30% 49(46.20%) 
3.  2.5 kg & above 21 39.60% 20 37.70% 41(38.70%) 
STATISTICAL 
INFERENCE 
χ2 = 0.295 Degree of freedom = 2 
0.863 > 0.05 
Not Significant 
 
47.20% and 45.30% babies of group A and B respectively had their birth weights 
ranging from 2 to 2.4 kg. The gestational age at admission of the majority of the 
patients was around 34 to 36 weeks in both the groups, with only a small percentage 
having an early onset disease. There was no significant difference in the outcome 
based on weight of the baby. 
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TABLE – 21 
NEONATAL INTENSIVE CARE ADMISSIONS 
S. 
NO. 
NICU 
ADMISSIONS 
 
GROUP A 
LABETALOL 
(n=53) 
 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
 
NUMBER 
 
% 
 
NUMBER 
 
% 
1.  
 
No 
46 86.80% 42 79.20% 88(83%) 
2.  
 
Yes 
7 13.20% 11 20.80% 18(17%) 
STATISTICAL 
INFERENCE 
 
χ2 = 1.071 Degree of freedom = 1 
0.301 > 0.05 
Not Significant 
 
The babies admitted to neonatal intensive care units were mostly due to the 
complications arising out of preterm labour. 17% of the enrolled mothers had their 
newborn admitted in intensive care unit. The difference did not vary significantly 
between the groups. 
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TABLE – 22 
NEONATAL OUTCOME MEASURES 
S. 
NO. 
NEONATAL 
OUTCOME 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  Alive 49 92.50% 46 86.80% 95(89.6%) 
2.  Dead 4 7.50% 7 13.20% 11(10.4%) 
STATISTICAL 
INFERENCE 
χ2= 0.913 Degree of freedom = 1 
0.339 > 0.05 
Not Significant 
 
Neonatal outcome was accounted on discharge of the mother. Out of 17% of intensive 
care admissions, 11% of the babies died. The major cause was from neonatal 
respiratory distress syndrome arising out of prematurity. Approximately 15% of the 
patients enrolled in the study had gestational age less than 28 weeks.  There was no 
significant change in terms of perinatal death in both the groups. 
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TABLE – 23 
ADVERSE EFFECTS 
S.NO. 
ADVERSE DRUG 
REACTIONS 
GROUP A 
LABETALOL 
(n=53) 
GROUP B 
NIFEDIPINE 
(n=53) 
TOTAL 
(n=106) 
NUMBER % NUMBER % 
1.  
No notable adverse 
effects 
35 66% 34 64.2% 69 (65.1%) 
2.  Dizziness 8 15.1% 3 5.7% 11 (10.4%) 
3.  Head ache 3 5.7% 6 11.3% 9 (8.5%) 
4.  Palpitation 0 0% 4 7.5% 4 (3.8%) 
5.  Nausea 3 5.7% 6 11.3% 9 (8.5%) 
6.  Tremor 2 3.8% 0 0% 2 (1.9%) 
7.  Pain at injection site 2 3.8% 0 0% 2 (1.9%) 
STATISTICAL INFERENCE 
χ2 = 12.287 Degree of freedom = 6 
0.056 > 0.05 
Not Significant 
No notable adverse effects were reported in the majority of the recruited patients. In 
group A, the common adverse effects were dizziness (15.10%) and head ache and 
nausea (5.7%). There were no instances of palpitations in group A. The common 
adverse effect of patients recruited in group B was head ache (11.3%). Similar 
number also complained of nausea in group B. 7.5% and 5.7% of patients in group B 
complained of palpitations and dizziness respectively. Overall, there was no 
significant difference in adverse effects in both the groups. 
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DISCUSSION 
Hypertensive emergency in pregnancy is associated with a considerable morbidity and 
mortality in both maternal and neonatal populations. The primary aim is to reduce the 
dangerously elevated blood pressure and ameliorate the severity of the disease.  
In the present study, intravenous labetalol was compared with oral nifedipine in terms 
of efficacy and safety. The maternal and fetal outcome measures and side effect 
profiles of the drugs were also studied. 
The patients enrolled in both the groups were comparable in terms of age, parity, 
booking status, gestational age at admission and body mass index. 
The mean age of the patients enrolled in the study was 24.89 years and 24.81 years in 
labetalol and nifedipine groups respectively.  
According to the study by Duckitt et al, primiparity is one of the risk factors for 
preeclampsia 
[54]
. In the present study, 75.47% of labetalol group and 50.94% of 
nifedipine group were primigravida.  
In the present study 40.57% patients presented in the gestational age of 34 to 36 
weeks. Early onset disease at gestational age of less than 24 weeks was seen in 2.83% 
of the enrolled patients.  
The progressive risk of preeclampsia in obese is elucidated in the study by Sibai and 
colleagues
 [55]
. The risk is said to be increased by 13.3% in women with body mass 
index more than 35 kg/m
2
. 62.30% of the patients enrolled in the labetalol and 
nifedipine groups fell under the category of obesity. 
All the patients enrolled in the study were homogenous in terms of protienuria. 
39.62% of patients in labetalol group and 43.40% of the patients in nifedipine group 
had 1+ proteinuria on urine dipstick estimation which approximates to 30 mg/dl of 
  
proteinuria. 34% of the enrolled patients had 3+ proteinuria which amounts to 1 to 2 
g/day of protienuria. 
In a randomized control trial conducted by Sibai, Brian, et al, on the expectant 
management of severe preeclampsia, the blood pressure on admission was found to be 
≥160/110 mm Hg [19].  Naidu, et al conducted a prospective study based on the finding 
through radiological investigative modalities such as single photon emission and 
cerebral computerised tomographic scan (SPECT) and transcranial Doppler findings 
in patients with eclampsia. 75% of the patients had perfusion defects in the watershed 
area in the parieto-occipital lobe arising out of cerebral vasospasm 
[56]
. The loss of 
cerebral autoregulation at elevated blood pressures, more particularly at a systolic 
blood pressure of more than 160 mm Hg, was theorized by Schwartz and co-workers 
in 2000 
[57]
.  
The mean systolic blood pressure of the patients enrolled in the labetalol and 
nifedipine groups in the present study was 171 mm Hg and 170 mm Hg, respectively. 
The mean diastolic blood pressure was 112 and 111 mm Hg in labetalol and 
nifedipine groups, respectively. 
According to the Cochrane database on review of drugs, the utility of the 
antihypertensive drug should be based on the experience of the clinician with respect 
to its utility and adverse effects. 
[4] 
In a double blind randomized trial by Raheem et al 
[58]
, it was shown that both 
labetalol and nifedipine are equally efficacious in controlling blood pressure. The 
reduction in systolic and diastolic blood pressure was comparable in both the groups. 
20% of the enrolled patients required cross-over treatment, in his trial.   
  
  
A similar study conducted by Vermilion
 [59]
 et al shows that oral nifedipine is superior 
when compared to labetalol in blood pressure control. The drug protocol used in the 
study differed from the present study. Vermilion used 20 mg oral nifedipine after the 
initial 10 mg dose. 
In the present study, out of the 53 patients enrolled in labetalol group, 20 patients, 
constituting 37.74% of the study population achieved the target blood pressure of ≤ 
150/100 mm Hg in 45 minutes of commencement of the treatment, requiring three 
incremental doses of intravenous labetalol. The total dose administered was in 
labetalol group was 140 mg. 
In the nifedipine group, 33.96% of the enrolled patients required two doses of oral 
nifedipine constituting a dose of 20 mg of the drug. However, on statistical analysis, 
there was no significant difference in the time taken for both the drugs to act for 
reduction in systolic blood pressure. On the whole, except for the 11 patients who 
required cross over treatment, all the patients constituting 89.60% attained blood 
pressure control at 75 minutes. 
On statistical analysis of the trend in reduction of the systolic blood pressure with 
respect to time, the difference of reduction in blood pressure was found to be 
significant at 30 minutes cut off. Oral nifedipine was found to be associated with a 
greater reduction in systolic blood pressure with respect to time. Similar trend was not 
seen in the case of reduction in diastolic blood pressure. Both the drugs were 
comparable in their reduction in diastolic blood pressure in the present study. 
Eleven patients, five in labetalol group and six in nifedipine group, comprising 
10.40% of the enrolled in the study, required cross over treatment. The number of 
doses of the other respective drugs after the crossover was similar in both the groups. 
  
The above mentioned patients achieved blood pressure control at 105 minutes after 
the commencement of the study.  
None of the enrolled patients developed hypotension during the study. The lowest 
blood pressure recorded during the study was 130/80 mm Hg. 
All the patients enrolled in the study received prophylactic magnesium sulphate 
therapy. None of the patients developed eclampsia in ante partum or post partum 
periods. The Magpie trial 
[37] 
recruiting 10141 women with preeclampsia showed that 
there was no significant interaction of nifedipine and magnesium sulphate. Similarly, 
in the present study, none of the patients receiving both the drugs developed 
hypotension or neuromuscular blockade. 
Sibai et al compared the maternal and neonatal outcomes in expectant versus 
aggressive management in severe preeclampsia in a specific set of population 
[19]
. The 
study showed better neonatal outcomes in terms of gestational age at delivery, birth 
weight and intensive care. 
Once the blood pressure was controlled, 97% of the enrolled patients in the present 
study were induced with cerviprime gel to expedite delivery. In patients with 
gestational age less than 34 weeks, steroids were administered after the control of 
blood pressure to accelerate the lung maturity. Fetal monitoring was done with non 
stress test before and after administration of anti hypertensive drugs and after 
induction of the patients. There was no cardiotocographic abnormality associated with 
the use of both the drugs.  
Among the patients enrolled, 69.80% delivered vaginally and 30.20% delivered by 
caesarean section. 49.20% of the babies delivered had their birth weights ranging 
from 2 to 2.4 kg. In patients with early onset disease and those associated with 
intrauterine growth restriction, the birth weight was less than 1.9 kg which made 
  
15.10% of the enrolled patients. There was no significant difference in birth weight in 
both the groups. 
13.20% of new born from labetalol group and 20.80% of new born from nifedipine 
group were admitted for intensive care. The causes of admission were extreme 
prematurity and respiratory distress syndrome. The outcome was similar in both the 
groups. None of the newborn had neonatal hypoglycaemia or hypotension after birth. 
Out of 17% of the newborn admitted for intensive care, 7.50% of newborn from 
labetalol group and 13.20% of newborn from nifedipine group died due to extreme 
prematurity. 
Majority of the patients enrolled in the study did not report any notable adverse 
effects. The most commonly reported adverse effect in labetalol group was dizziness 
and that in nifedipine group was head ache and nausea. None of the patients in the 
labetalol group had palpitations, though 7.5% of patients in the nifedipine group had 
complained of the same. 3.8% of the patients enrolled in the labetalol group had 
complained of tremor and pain at the injection site. On the whole, there was no 
statistically significant difference in adverse effects between both the groups.  
The present study has certain limitations. The blood pressure and drug titration after 
the initial control of hypertension was not taken into account in the study. None of the 
patients with severe preeclampsia were managed expectantly because of the 
institutional protocol.  
  
  
SUMMARY 
 In the present study, out of the 106 antenatal patients with sustained severe 
hypertension, 53 were randomized to receive intravenous labetalol treatment 
and the rest were randomized to oral nifedipine treatment and the two groups 
were compared in terms of efficacy and safety of the treatment, adverse effects 
and maternal and perinatal outcome measures. 
 All the patients recriuited in the study achieved blood pressure control. 
Majority of the patients in labetalol group (37.74%) achieved target blood 
pressure at 45 minutes and that with the nifedipine group (33.96%) achieved 
the target blood pressure at 30 minutes. 
 25.80% in labetalol group received three doses of the drug. 26.40% of the 
patients received two doses of the drug in nifedipine group.  
 The rate of fall of blood pressure was the highest at 45 minutes for labetalol 
group and at 30 minutes for the nifedipine group. 
 10.40% of the patients required more than five doses and the treatment was 
crossed over to the other respective groups. All the patients in the cross over 
group achieved target blood pressure within 105 minutes. 
 None of the patients had hypotensive episodes. There were no instances of 
fetal cardiotocographic abnormalities during the trial period. 
 Both the groups exhibited significant differences in heart rate after 30 minutes 
of the commencement of the treatment. The heart rate declined with respect to 
time in the labetalol group. There was a rise in heart rate in the nifedipine 
group. 
  
 91.50% of the enrolled patients were induced to expedite delivery. 66% in 
labetalol group and 73.60% in nifedipine group delivered vaginally. 
 There was no maternal mortality. All the patients were discharged without any 
residual complications. Perinatal mortality was 7.50% and 13.20% in labetalol 
and nifedipine group respectively.  
 No notable adverse effect was reported by 65.10% of the patients. 15.10% of 
patients in labetalol group had dizziness. 11.3% of the patients in nifedipine 
group had headache and nausea. 
  
  
CONCLUSION 
Management of severe preeclampsia is in the control of blood pressure, prevention of 
complications, fetal surveillance and expedition of delivery if indicated. In the present 
study, the trend in reduction of blood pressure in patients with sustained severe 
hypertension with the use of intravenous labetalol and nifedipine was compared.  
From the present study, both the drugs were found to be safe and effective in the 
reduction of blood pressure. None of the drugs were associated with any detrimental 
maternal or fetal outcomes with respect to the anti hypertensive usage. The tolerance 
of the patients towards both the drugs was similar.  
Intravenous labetalol provided a smooth and steady reduction in blood pressure. The 
use of nifedipine may be recommended in low resource settings since it has an oral 
regimen and dosage is simple when compared to incremental intravenous dosing of 
labetalol.  
In conclusion, both intravenous labetalol and oral nifedipine are equally efficacious 
and can be used as first line drugs for the use in acute blood pressure control of 
hypertensive emergency of pregnancy. 
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PROFORMA 
A RANDOMIZED TRIAL OF INTRAVENOUS LABETALOL VERSUS ORAL 
NIFEDIPINE IN ACUTE BLOOD PRESSURE CONTROL IN 
HYPERTENSIVE EMERGENCIES OF PREGNANCY 
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11 65049 Ilakiya 29 primi 32 2 32.6 166 116 90 1 1 15 1 150 
    
90 
     
90 
    
1 24 2 2.5 0 1 1 
12 109 Anandhi 18 G3P2L2 34 1 33.6 174 118 100 3 2 45 3 160 160 150 
  
118 118 100 
   
100 100 102 
  
1 24 1 2.6 0 1 1 
13 234 Rani 22 primi 32 2 30.8 170 110 102 1 2 45 3 160 150 150 
  
110 110 100 
   
102 100 100 
  
1 30 1 2.7 0 1 2 
14 375 Gayathri 27 primi 36 2 29.7 160 110 90 2 1 45 3 160 160 150 
  
110 110 100 
   
90 90 90 
  
1 9 2 2.8 0 1 0 
15 2996 Arthi 19 G2P1L1 34 1 30.4 166 114 98 1 2 30 2 160 150 
   
110 90 
    
98 98 
   
1 4 1 2.5 0 1 0 
16 3124 Malliga 28 primi 24 1 29.8 176 120 96 1 1 45 3 170 170 150 
  
120 116 90 
   
96 96 96 
  
1 30 1 1.5 1 2 0 
17 3143 Vasantha 32 primi 28 1 30.9 160 110 90 1 2 30 2 160 150 
   
104 90 
    
90 98 
   
1 32 1 1.6 1 1 0 
18 4309 Seshi 26 G2P1L1 36 2 31.5 162 114 88 3 1 30 2 160 150 
   
114 98 
    
88 88 
   
1 5 1 2.4 0 1 0 
19 4352 Samanasu 30 primi 38 1 32.6 176 130 86 3 2 30 2 170 140 
   
110 90 
    
86 88 90 
  
1 2 2 3 0 1 0 
20 4580 Radhika 23 primi 36 1 29.1 166 120 102 2 1 60 4 160 160 150 150 
 
120 118 110 100 
  
102 100 98 98 
 
1 3 1 2.7 0 1 0 
21 4590 Devika 29 G4P3L3 32 1 31.8 162 110 100 1 2 45 3 162 162 150 
  
110 100 90 
   
100 100 98 
  
1 24 1 2.2 0 1 0 
22 13488 Devi 28 primi 34 2 33.8 172 110 98 3 2 45 3 160 160 150 
  
110 100 90 
   
98 98 98 
  
1 6 1 2.7 0 1 0 
23 13894 Suganya 21 primi 34 1 30.2 180 100 90 1 1 105 7 180 178 178 170 170 100 104 90 90 88 1 90 90 90 88 88 1 8 1 2.5 0 1 1 
24 13996 Suguna 29 G3P2L2 30 1 28.5 200 120 88 2 2 90 6 180 180 178 170 170 120 118 118 110 110 1 88 90 98 98 100 1 30 1 2.1 1 1 0 
25 14100 Logambal 18 primi 36 2 33.5 166 100 86 1 2 75 5 166 166 160 160 158 100 100 90 90 88 
 
88 88 90 98 98 0 3 2 2.9 0 1 2 
26 14122 Podumponu 24 primi 32 2 32.9 160 110 90 1 1 60 4 160 160 150 148 
 
110 110 110 98 
  
90 90 90 80 
 
1 24 2 2.3 0 1 0 
  
27 14141 Selvi 19 G2P1L1 34 2 30.8 170 120 80 3 2 45 3 170 168 150 
  
120 128 100 
   
80 90 100 
  
1 24 1 2.6 0 1 0 
28 14261 Indrani 25 G2P1L1 38 1 28.9 170 110 78 3 2 75 5 170 168 160 160 150 110 110 110 110 100 
 
78 80 88 88 90 1 4 1 2.8 0 1 0 
29 14266 Chithra 30 primi 38 1 30.9 160 110 70 1 1 45 3 160 160 148 
  
110 110 90 
   
70 70 80 
  
1 6 1 3 0 1 1 
30 14339 Prema 24 G4P3L3 30 2 34.1 164 110 88 1 2 60 4 164 160 150 150 
 
110 110 108 90 
  
88 88 98 98 
 
1 36 1 2.3 0 1 0 
31 14495 Mariammal 29 primi 34 2 33.1 172 110 80 3 2 60 4 160 160 160 140 
 
110 108 100 90 
  
80 90 90 98 
 
1 6 1 2.2 0 1 2 
32 14702 Kavitha 28 G3P2L1 32 2 29.1 178 104 78 1 2 45 3 170 160 150 
  
100 90 90 
   
78 80 90 
  
1 12 1 2.1 0 1 2 
33 15418 Eswari 20 primi 36 1 32.4 170 110 76 2 2 30 2 160 150 
   
100 90 
    
76 80 
   
1 8 1 2.8 0 1 1 
34 15449 Nazeema 31 G2P1L1 34 1 33.9 168 112 74 2 1 45 3 160 158 140 
  
112 100 90 
   
74 74 74 
  
1 10 1 3 0 1 0 
35 15663 Kavitha 31 primi 36 1 30.7 164 100 78 3 2 30 2 160 140 
   
90 88 
    
80 90 
   
1 7 2 2.8 0 1 0 
36 16231 Firdose 24 primi 30 2 32.1 160 110 80 2 1 45 3 160 160 150 
  
100 90 80 
   
80 80 78 
  
1 24 2 2.4 0 1 0 
37 16421 Palaniamal 30 G2P1L1 36 2 32.3 160 120 90 3 2 30 2 160 140 
   
110 90 
    
90 100 
   
0 8 1 2.8 0 1 3 
38 20642 Radhika 34 primi 38 1 34.3 170 120 100 3 1 45 3 170 168 150 
  
110 100 90 
   
100 98 90 
  
1 4 2 3 0 1 0 
39 20869 Jeya 29 primi 34 1 35.1 168 122 98 2 2 45 3 150 150 140 
  
120 110 98 
   
98 98 98 
  
1 4 2 2.8 0 1 0 
40 20943 Vinodha 31 primi 34 1 31.7 172 100 90 3 1 45 3 170 158 140 
  
90 90 80 
   
90 90 88 
  
1 8 2 2.8 0 1 1 
41 21193 Jamuna 28 G3P2L2 32 1 29.7 170 110 80 2 2 60 4 170 160 160 150 
 
110 110 110 90 
  
80 88 98 
  
1 24 1 2.3 0 1 2 
42 21432 Sajinisha 23 G3P2L1 30 2 29.1 180 110 78 3 1 60 4 180 176 160 148 
 
100 98 90 90 
  
78 78 80 78 
 
1 30 1 2 0 1 2 
43 21723 Mersiyal 20 primi 36 2 30.5 180 114 90 3 1 75 5 180 170 170 150 
 
114 100 90 90 
  
90 90 88 80 80 1 6 1 2 0 1 0 
44 21859 Suseela 23 G3P2L0 28 1 34.1 178 120 80 3 1 60 4 170 168 160 140 
 
110 100 90 90 
  
80 80 80 80 
 
1 32 1 1.6 1 1 0 
45 21888 Ramya 27 primi 34 1 29.8 160 110 76 2 2 30 2 160 148 
   
100 90 
    
78 80 
   
1 6 2 2 0 1 0 
46 21892 Vijaya 33 primi 36 1 25.8 180 112 86 2 1 45 3 180 180 150 
  
112 110 98 
   
86 80 80 
  
1 7 2 2.5 0 1 1 
47 21918 Mani 20 primi 34 1 29.4 166 114 98 2 1 30 2 160 150 
   
110 90 
    
98 90 
   
1 6 2 2 0 1 0 
48 22197 Danam 27 G2P1L1 33 2 30.4 176 100 90 2 2 30 2 170 148 
   
90 88 
    
90 100 
   
1 28 1 2 0 1 0 
49 23750 Satya 29 primi 28 1 33.1 178 110 100 1 1 15 1 150 
    
90 
     
100 
    
1 30 1 1.8 1 1 6 
50 23928 Tamarai 29 G2P1L1 24 1 29.6 170 112 88 1 2 45 3 160 148 140 
  
112 110 90 
   
88 90 90 
  
1 36 1 1 1 2 0 
51 24233 Ammu 18 primi 32 1 28.2 160 116 90 1 2 45 3 160 158 140 
  
100 90 88 
   
90 90 96 
  
1 24 2 2 1 1 0 
52 24261 Chellaya 29 primi 34 1 35.3 200 118 98 3 1 105 7 200 180 180 178 170 118 110 100 100 100 1 98 90 90 88 88 1 7 1 2.1 0 1 0 
53 24801 Rajeswari 20 G3P1L1A1 38 1 29.5 160 120 90 1 2 60 4 160 158 150 140 
 
120 118 110 100 
  
90 98 98 98 
 
1 4 1 3 0 1 0 
54 24853 Sundarambal 19 primi 32 1 28.6 166 110 90 2 1 45 3 160 158 140 
  
110 90 88 
   
90 90 90 
  
1 6 1 2.8 0 1 0 
55 24856 Mumtaj 24 G4P1L1A2 34 2 26.4 160 114 90 2 2 75 3 160 150 148 
  
110 100 90 
   
90 92 100 
  
1 3 1 2 0 1 0 
56 24981 Vimala 30 G2P1L1 28 1 29.1 170 118 90 3 1 90 6 170 170 170 168 160 118 110 110 110 100 1 90 90 80 80 80 1 24 1 2.5 0 1 6 
57 25292 Prabavati 22 primi 26 1 28.5 178 120 92 3 2 75 5 170 170 168 160 150 110 100 100 90 90 
 
92 90 94 98 100 1 20 1 1.2 1 2 0 
58 25385 Sheelamary 21 primi 32 2 30.5 176 110 94 3 1 75 5 170 160 158 150 140 110 100 100 90 88 
 
94 90 90 88 88 1 6 2 2.1 0 1 0 
59 25412 Amsavalli 26 primi 32 2 27.5 180 106 98 1 1 60 4 180 178 170 160 
 
106 100 90 88 
  
98 90 88 88 
 
1 8 2 2 0 1 0 
60 25847 Malathy 25 primi 26 1 32.5 180 118 90 1 2 90 6 180 178 170 170 160 110 110 110 110 100 1 90 94 98 98 100 1 30 2 1 1 2 0 
61 26056 Panjavarnam 28 primi 30 1 32.4 170 110 70 1 1 75 5 170 170 168 160 150 110 110 108 100 90 
 
70 70 72 70 70 1 9 1 2 0 1 0 
62 26272 Yogarani 26 G2P1L1 26 1 29.7 170 120 74 2 2 75 5 170 160 160 158 150 120 110 110 108 90 
 
84 88 90 90 90 1 26 1 1.2 1 2 0 
63 26457 Sangaatha 30 G2P1L1 28 1 32.5 170 116 70 1 1 60 4 168 160 150 140 
 
110 110 106 98 
  
70 72 70 70 
 
1 30 1 1 1 2 0 
64 26521 Kalaivani 31 primi 32 2 28.5 166 116 78 2 1 45 3 150 150 148 
  
116 110 100 
   
78 80 80 
  
0 10 1 2 0 1 0 
65 26610 Jenitha 22 primi 34 2 27.9 176 110 70 2 2 15 1 150 
    
100 
     
70 
    
1 9 1 2.2 0 1 0 
66 26730 Periyakke 26 primi 36 1 29.1 160 110 88 1 1 105 7 160 160 160 158 150 110 110 110 110 110 1 88 88 90 88 90 1 8 1 2.6 0 1 0 
67 26790 Jeeva 28 primi 34 1 27.2 160 110 80 3 2 75 5 160 158 156 150 140 110 110 106 106 98 
 
80 82 88 90 90 1 6 2 2.4 0 1 0 
68 26908 Pongodi 21 G4P2L1A1 32 1 33 160 120 70 3 1 75 5 160 160 158 150 140 120 118 100 98 88 
 
70 70 68 70 72 0 6 1 2.1 0 1 0 
69 27052 Chithra 27 primi 34 1 33.8 166 100 74 1 2 30 2 150 140 
   
100 90 
    
74 80 
   
1 8 1 2.1 0 1 0 
  
70 27123 Vijaya 22 G3P1L1A1 32 2 32.9 172 100 70 1 2 105 7 172 170 170 170 160 100 98 90 90 90 1 72 78 88 88 90 1 8 1 2.2 0 1 0 
71 27142 Vasantha 20 primi 28 1 34.5 170 106 70 1 1 60 4 170 170 160 150 
 
100 90 90 90 
  
70 70 70 68 70 1 30 1 1.5 1 2 0 
72 27413 Geetha 19 G2P1L1 36 1 32.1 166 120 80 2 1 60 4 166 160 150 140 
 
110 110 108 80 
  
80 80 86 86 
 
1 5 1 2 0 1 0 
73 27463 Nadhiya 20 primi 30 1 33.1 164 120 88 1 1 45 4 164 160 160 140 
 
120 110 110 100 
  
88 80 80 80 
 
0 3 2 2 0 1 0 
74 27531 Logambal 19 G2P1L1 34 2 32.5 160 112 80 3 2 75 3 160 140 130 
  
112 110 90 
   
82 88 90 
  
1 5 1 2.1 0 1 0 
75 27574 Manimegalai 28 primi 36 2 29.4 170 100 80 1 1 15 1 150 
    
90 
     
82 
    
1 6 2 2.5 0 1 0 
76 27596 Rajeshwari 20 primi 38 2 29.9 170 102 90 1 2 60 4 160 158 158 150 
 
102 100 100 90 
  
92 98 98 100 
 
0 3 2 3 0 1 3 
77 27798 Banumathy 29 primi 36 2 28.5 170 110 90 1 1 45 3 170 160 150 
  
110 100 90 
   
90 90 88 
  
1 5 1 2.5 0 1 0 
78 28127 Saradha 23 G4P3L3 32 2 30.5 172 100 100 2 1 60 4 172 170 150 
  
100 98 88 
   
100 100 98 90 
 
0 2 1 2.5 0 1 0 
79 28376 Anusha 26 primi 34 2 31.6 166 110 106 3 1 75 5 166 160 140 
  
100 90 90 
   
104 100 90 90 90 1 5 1 2 0 1 0 
80 28523 Jansirani 28 G3P1L1A1 36 2 32.5 168 120 88 3 2 30 2 160 140 
   
110 98 
    
88 80 
   
1 4 1 2 0 1 1 
81 28646 Chandra 24 primi 32 1 29.8 160 114 90 1 1 75 5 160 158 150 140 
 
114 110 110 100 
  
90 90 88 90 90 1 3 2 2.1 0 1 0 
82 28710 Maheswari 29 G4P1L1A2 34 2 30.4 170 120 98 1 2 60 4 170 160 160 148 
 
110 110 108 90 
  
98 98 96 98 
 
1 1 2 1.8 1 1 0 
83 28783 Usha 30 primi 30 2 32.6 170 100 72 2 2 30 2 160 148 
   
100 90 
    
72 80 
   
1 2 2 2.1 0 1 1 
84 28996 Mani 21 primi 38 2 31.5 172 100 80 2 1 45 3 170 168 150 
  
100 90 88 
   
80 80 80 
  
1 3 2 3 0 1 4 
85 29184 Rajathi 19 G2P1L1 36 2 29.4 174 100 68 3 2 105 7 174 170 160 160 160 100 100 100 100 100 1 70 80 88 98 98 1 5 1 3 0 1 4 
86 29327 Revathy 20 primi 38 2 28.9 170 110 70 3 2 60 4 168 160 150 150 
 
110 108 108 98 
  
78 88 88 90 
 
1 3 2 3.1 0 1 4 
87 30730 Amudha 30 primi 28 1 33.9 180 104 64 1 2 60 4 178 170 168 146 
 
100 98 90 88 
  
70 78 90 90 
 
1 30 1 1.6 1 2 4 
88 30939 Vanitha 30 primi 30 1 38.1 182 100 68 1 1 90 5 182 180 170 150 
 
100 100 98 90 
  
68 70 70 72 72 1 6 1 2 0 1 5 
89 31411 Shameem 22 primi 30 1 32.5 180 100 70 1 2 30 2 170 150 
   
100 80 
    
70 78 
   
1 6 2 2.1 0 1 0 
90 31623 Ranjitha 27 primi 28 1 27.1 180 102 74 1 1 30 2 180 150 
   
90 80 
    
76 70 
   
1 24 2 1.8 1 2 0 
91 31774 Priya 26 G3P2L2 30 2 26.7 184 104 80 3 2 30 2 170 148 
   
90 80 
    
88 88 
   
1 20 1 2.5 0 1 4 
92 31929 Jeenath 25 primi 32 2 29.7 180 120 88 3 1 30 2 140 
    
100 90 
    
88 86 
   
1 30 1 2 0 1 0 
93 32119 Rinku 24 primi 36 2 33.2 166 104 90 2 1 45 3 160 158 130 
  
90 90 80 
   
90 90 88 
  
0 2 2 2.3 0 1 5 
94 32321 Sheela 24 primi 28 1 35.6 170 100 94 2 2 30 2 160 140 
   
100 80 
    
94 94 
   
1 24 1 1.4 1 2 0 
95 32336 Shobana 21 primi 30 2 31.3 172 104 80 1 2 45 3 168 160 140 
  
100 90 88 
   
80 88 90 
  
1 7 1 2 0 1 1 
96 49140 Meena 30 G2P1L1 32 1 28.2 170 104 70 1 2 45 3 170 168 150 
  
100 90 80 
   
78 80 90 
  
1 6 1 2.2 0 1 0 
97 49205 Sofia 18 primi 28 1 28.9 170 100 64 2 1 15 1 150 
    
90 
     
68 
    
1 24 1 1.2 1 1 4 
98 49241 Jothi 20 G3P1L1A1 30 1 30.5 166 112 68 2 2 30 2 150 140 
   
110 90 
    
70 80 
   
1 8 1 2 0 1 4 
99 49396 Lalitha 19 primi 34 2 32.7 180 120 70 2 2 105 7 180 180 170 168 160 120 120 120 118 110 1 70 78 80 80 86 1 5 2 2 0 1 4 
100 49538 Nadhiya 21 primi 36 2 31.5 200 122 70 1 1 45 3 180 160 150 
  
118 110 100 
   
70 70 72 
  
1 5 2 2.2 0 1 0 
101 50035 Geetha 24 G2P1L1 30 2 32.4 178 120 80 1 2 105 7 178 176 170 168 160 120 120 120 110 110 1 80 80 84 90 98 1 7 1 2 0 1 3 
102 52110 Hema 18 primi 30 2 32.6 188 114 88 1 1 90 6 188 180 180 170 170 110 110 110 100 100 1 88 80 80 78 80 1 8 1 2 0 1 0 
103 52454 Buvaneswari 20 primi 34 1 28.9 180 100 90 1 1 45 3 170 158 150 
  
90 90 80 
   
90 90 80 
  
1 10 1 2.5 0 1 0 
104 52730 Vasantha 24 primi 38 2 30.5 170 100 80 3 1 60 4 170 170 160 150 
 
100 90 90 90 
  
80 80 82 78 
 
0 8 1 3 0 1 0 
105 52988 Annakamu 23 primi 36 2 26.7 168 114 88 3 1 30 2 160 150 
   
100 90 
    
88 88 
   
1 8 2 2.5 0 1 4 
106 53401 Rosemary 25 G2P1L1 38 2 30.5 172 118 80 1 2 60 4 160 158 150 
  
118 110 100 90 
  
80 82 88 90 
 
1 5 1 3 0 1 3 
  
ABBREVIATIONS 
BOOKING 
1 Booked 
2 Unbooked 
GROUP 
1 Labetalol 
2 Nifedipine 
GA   Gestational Age 
BMI   Body Mass Index 
SYS BP  Systolic Blood Pressure 
DIAS BP  Diastolic Blood Pressure 
HR   Heart Rate 
INDUCTION 
0   Induction with cerviprime gel 
1   No induction 
MODE OF DELIVERY 
1 Labour natural 
2 Caesarean section 
NICU (NEONATAL INTENSIVE CARE UNIT) ADMISSION 
0 Not admitted 
1 Admitted in NICU 
NEONATAL OUTCOME 
1. Alive 
2. Dead 
ADR (ADVERSE DRUG REACTIONS) 
0 No notable adverse effects 
1 Dizziness 
2 Headache 
3 Palpitations 
4 Nausea 
  
5 Tremor 
6 Pain at the injection site 
7 Wheezing 
IUGR    intrauterine growth restriction 
sFLT     soluble fms- like tyrosine kinase 
VEGF     vascular endothelial growth factor 
PDGF     platelet derived growth factor 
PGI2     prostaglandin I2 
PGE2     prostaglandin E2 
KIR     killer cell immunoglobulin like receptor 
HLA    human leukocyte antigen 
NK cells   natural killer cells 
MRI    magnetic resonance imaging 
HELLP   hemolysis, elevated liver enzymes, low platelet count 
 
